BioPharma Dive ٦ أبريل ٢٠٢٦ Under-the-skin Tepezza comparable to infused version in key study, Amgen says
BioPharma Dive ٢ أبريل ٢٠٢٦ Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
BioPharma Dive ١ أبريل ٢٠٢٦ Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive ١ أبريل ٢٠٢٦ A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma